首页 | 本学科首页   官方微博 | 高级检索  
     


Balloon-Expandable Valve for Treatment of Evolut Valve Failure: Implications on Neoskirt Height and Leaflet Overhang
Affiliation:1. Centre for Heart Valve Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, Canada;2. Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, Canada;3. Cardiovascular Translational Laboratory, Vancouver, Canada;4. Edith Wolfson Medical Center, Holon, Israel;5. Tel-Aviv University, Tel-Aviv, Israel;6. Department of Cardiovascular Surgery, Mount Sinai Health System, New York, New York, USA;7. Department of Cardiothoracic Surgery, Pinnacle Health, Harrisburg, Pennsylvania, USA;8. MedStar Washington Hospital Center, Washington, DC, USA;9. Department of Cardiovascular Surgery, Abrazo Arizona Heart Hospital, Phoenix, Arizona, USA;10. Division of Cardiovascular and Thoracic Surgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York, USA;11. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA;12. Department of Cardiovascular and Thoracic Surgery, Morton Plant Hospital, BayCare Health System, Clearwater, Florida, USA;13. The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;14. Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USA;15. Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia, USA;p. Research and Development, Structural Heart & Aortic, Medtronic, Santa Ana, California, USA
Abstract:ObjectivesThis study sought to determine the degree of Evolut (Medtronic) leaflet pinning, diameter expansion, leaflet overhang, and performance at different implant depths of the balloon-expandable Sapien 3 (S3, Edwards Lifesciences LLC) transcatheter heart valve (THV) within the Evolut THV.BackgroundPreservation of coronary access and flow is a major factor when considering the treatment of failed Evolut THVs.MethodsAn in vitro study was performed with 20-, 23-, 26-, and 29-mm S3 THVs deployed within 23-, 26-, 29-, and 34-mm Evolut R THVs, respectively. The S3 outflow was positioned at various depths at node 4, 5, and 6 of the Evolut R. Neoskirt height, leaflet overhang, performance, and Evolut R valve housing diameter expansion were assessed under physiological conditions as per ISO 5840-3 standard.ResultsThe neoskirt height for the Evolut R was shorter when the S3 outflow was positioned at node 4 compared with node 6 (node 4 height for 23 mm = 16.3 mm, 26 mm = 17.1 mm, 29 mm = 18.3 mm, and 34 mm = 19.9 mm vs node 6 height for 23 mm = 23.9 mm, 26 mm = 23.4 mm, 29 mm = 24.7 mm, and 34 mm = 27 mm Evolut R). All configurations exhibited acceptable hydrodynamic performance irrespective of the degree of leaflet overhang, except the 29-mm S3 implanted in 34-mm Evolut R at node 4 (regurgitant fraction >20%). The valve housing radius of the index Evolut R increased when the S3 was implanted, with the increase ranging from 0 to 2.5 mm.ConclusionsPlacement of the S3 at a lower implant position within an index Evolut R reduces the neoskirt height with no significant compromise to S3 valve function despite a higher degree of leaflet overhang. Low S3 implantation may facilitate future coronary access after redo transcatheter aortic valve replacement.
Keywords:aortic stenosis  bench study  redo transcatheter aortic valve replacement  S3"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0035"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  Sapien 3  TAVR"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0045"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  transcatheter aortic valve replacement  THV"  },{"  #name"  :"  keyword"  ,"  $"  :{"  id"  :"  kwrd0055"  },"  $$"  :[{"  #name"  :"  text"  ,"  _"  :"  transcatheter heart valve
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号